Healthcare ❯ Pharmaceuticals

Rare Diseases

CNS Disorders Orphan Drug Designation Gene Therapy Candidates Neurological Disorders Product Launches Friedreich's Ataxia Drug Development Transthyretin Amyloidosis H3 K27M-Mutant Glioma Neuromuscular Diseases Drug Treatments Tumor Treatments Cortrophin Gel Cancer Treatments Prader-Willi Syndrome

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

The all-cash deal gives the Italian group a U.S. foothold to scale a Brain Health–focused rare-disease platform.

Neurocrine to Acquire Soleno for $2.9 Billion in All-Cash Tender

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Blog Jobs Terms of Service Privacy Policy Cookies Help Partners About Us Copyright © 2026 Mina Labs, Inc.

We value your privacy

We and our partners use cookies and similar technologies to understand how you use our site and to show you personalized advertisements on other platforms. By clicking "Accept All," you consent to these technologies for advertising, analytics and retargeting. Click "Decline All" to opt out of non-essential cookies. You can learn more in our Privacy Policy.